Known targets — ChEMBL curated mechanism
BTKCACNA1CCACNA1DCACNA1FCACNA1SCACNA2D1CACNA2D2DRD2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQHRH1HTR2AP2RY12
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.45 |
| ▸ | ATR | Q13535 | 1/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.45 |
| ▸ | ATRIP | Q8WXE1 | 1/20 | 0.45 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.41 |
| ▸ | MTOR | P42345 | 12/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7044550 | 0.94 | ATR (0.45) | CHEK1ATRPDCD1ATRIPCD274 | |
| SCHEMBL7046842 | 0.91 | MAPK1 (0.48) | CHEK1ATRPDCD1ATRIPCD274 | |
| SCHEMBL7045657 | 0.72 | NPSR1 (0.48) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL7048583 | 0.72 | NPSR1 (0.48) | ATRMAPTCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7458020 | 0.66 | MTOR (0.50) | ATRATRIPMAPTCYP1A2CYP3A4 | |
| SCHEMBL6956055 | 0.64 | SMN1; SMN2 (0.40) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL2628838 | 0.62 | MAPT (1.00) | MAPTCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL20651545 | 0.62 | CHEK1 (1.00) | CHEK1ATRPDCD1ATRIPCD274 | |
| SCHEMBL6694832 | 0.62 | SMN1; SMN2 (0.41) | MAPTCYP1A2CYP2C9CYP2C19MAPK1 | |
| SCHEMBL6699244 | 0.62 | MAPT (0.38) | MAPTCYP1A2CYP3A4CYP2C19MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12570627-B2 | Pharmaceutical composition in which production of impurities is suppressed | SHIONOGI & CO., LTD. (JP) | 2026-03-10 | — | — | US | disclosed |
| US-6599911-B2 | Particularly useful in treating and suppressing human Cytomegalovirus | TULARIK INC. | 2003-07-29 | — | — | US | disclosed |
| US-20030130264-A1 | Methods of using pyrimidine-based antiviral agents | TULARIK INC. (US) | 2003-07-10 | — | — | US | disclosed |
| US-20030045715-A1 | Arylsulfonic acid salts of pyrimidine-based antiviral agents | TULARIK INC. (US) | 2003-03-06 | — | — | US | disclosed |
| EP-1248783-A1 | ARYLSULFONIC ACID SALTS OF PYRIMIDINE-BASED ANTIVIRAL AGENTS | Tularik Inc. (US) | 2002-10-16 | — | — | EP | disclosed |
| US-6410726-B1 | USEFUL IN TREATING AND SUPPRESSING HUMAN CYTOMEGALOVIRUS | TULARIK INC. | 2002-06-25 | — | — | US | disclosed |
| US-20020065279-A1 | Useful in treating and suppressing human Cytomegalovirus | AMGEN INC. | 2002-05-30 | — | — | US | disclosed |
| WO-2001051485-A1 | ARYLSULFONIC ACID SALTS OF PYRIMIDINE-BASED ANTIVIRAL AGENTS | TULARIK INC. (US) | 2001-07-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020065279-A1 | Useful in treating and suppressing human Cytomegalovirus | TPMT, MGMT, NSUN2 | CHEK1 1173/4885ATR 676/4885PDCD1 1002/4885 |
| US-20030130264-A1 | Methods of using pyrimidine-based antiviral agents | TYMP, TYMS, NUDT1 | CHEK1 553/4885ATR 670/4885PDCD1 1454/4885 |
| US-20030045715-A1 | Arylsulfonic acid salts of pyrimidine-based antiviral agents | PNP, TPMT, NSUN2 | CHEK1 896/4885ATR 166/4885PDCD1 1435/4885 |
| US-12570627-B2 | Pharmaceutical composition in which production of impurities is suppressed | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KIF15, WDR12 | CHEK1 4222/4885ATR 3296/4885PDCD1 2174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.